A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
This is a a Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort
Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in
Combination with MGD013 in Patients with Advanced or Metastatic Solid Tumor Who Failed Prior
Treatment.
This study consists of dose escalation part and dose expansion part.'3+3'design will be
adopted in the dose escalation part in subjects with advanced or metastatic gastric cancer
who failed prior treatment. The dose of niraparib will be fixed and determined based on
baseline weight and platelet count of subjects. Dose expansion part will be expanded at the
specified dose level to further assess the safety and preliminary antitumor activity.